Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Spero Therapeutics, Inc. (NASDAQ: SPRO).

Full DD Report for SPRO

You must become a subscriber to view this report.


Recent News from (NASDAQ: SPRO)

Spero Therapeutics Announces Positive Results from SPR720 IND-Enabling Studies and Plans to Initiate a Phase 1 Trial
CAMBRIDGE, Mass., Nov. 05, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections, today announced re...
Source: GlobeNewswire
Date: November, 05 2018 08:00
Spero Therapeutics to Present at the Cantor Global Healthcare Conference in October
CAMBRIDGE, Mass., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, announced today that Joel...
Source: GlobeNewswire
Date: September, 19 2018 08:00
Spero Therapeutics to Present New Data for SPR994 and SPR206 at ESCMID/ASM 2018 Conference
Highlights include eleven presentations covering SPR994’s pharmacokinetics and pharmacodynamics, SPR206’s broad spectrum of activity and favorable toxicology, and urinary tract infection epidemiology CAMBRIDGE, Mass., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, I...
Source: GlobeNewswire
Date: August, 28 2018 08:00
Analysis: Positioning to Benefit within Noble, Spero Therapeutics, AK Steel Holding, Matrix Service, First Internet, and Cray - Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Aug. 22, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Noble Corporation (NYSE:NE), Spero Therapeutics, Inc. (NASDAQ:SPRO), AK S...
Source: GlobeNewswire
Date: August, 22 2018 07:30
Our First Look At Spero Therapeutics
I have enough money to last me the rest of my life, unless I buy something .” ― Jackie Mason Today, we take our first look at a small ‘ Tier 4 ’ biotech concern that has only been on the market for nine months. Company Overview: Spero Therapeutics, In...
Source: SeekingAlpha
Date: August, 21 2018 10:14
Entasis Therapeutics files for $86.25M initial public offering
Clinical-stage biopharmaceutical firm Entasis Therapeutics has filed for an initial public offering for up to $86.25M. More news on: Tetraphase Pharmaceuticals, Shionogi & Co. Ltd. ADR, GlaxoSmithKline, Healthcare stocks news, IPOs, Read more ...
Source: SeekingAlpha
Date: August, 17 2018 18:15
Spero Announces Appointment of John C. Pottage, Jr., MD to its Board of Directors
CAMBRIDGE, Mass., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multidrug-resistant bacterial infections, today announced the appoin...
Source: GlobeNewswire
Date: August, 14 2018 08:00

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-146.836.386.896.1523,249
2018-12-136.716.796.886.5282,068
2018-12-126.906.707.176.7039,700
2018-12-116.806.907.156.557334,636
2018-12-106.756.726.956.5221,765

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-142,0138,68323.1832Cover
2018-12-1312,24833,04637.0635Short
2018-12-123,88010,98435.3241Short
2018-12-113,84412,43330.9177Cover
2018-12-102,5079,80425.5712Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on SPRO.


About Spero Therapeutics, Inc. (NASDAQ: SPRO)

Logo for Spero Therapeutics, Inc. (NASDAQ: SPRO)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: SPRO)

      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 14 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: August, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: August, 09 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 17 2018
      Amendment to a SC 13D filing
      Filing Type: SC 13D/AFiling Source: edgar
      Filing Date: July, 17 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 16 2018
      Prospectus filed under Rule 424(b)(4)
      Filing Type: 424B4Filing Source: edgar
      Filing Date: July, 13 2018
      Notice from the SEC of registration effectiveness
      Filing Type: EFFECTFiling Source: edgar
      Filing Date: July, 12 2018
      Amendment to general form for registration of securities under the Securities Act of 1933
      Filing Type: S-1/AFiling Source: edgar
      Filing Date: July, 11 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: July, 09 2018

       

       


      Daily Technical Chart for (NASDAQ: SPRO)

      Daily Technical Chart for (NASDAQ: SPRO)


      Stay tuned for daily updates and more on (NASDAQ: SPRO)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: SPRO)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in SPRO is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of SPRO and does not buy, sell, or trade any shares of SPRO. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/